Based on the profound effect of Blimp1 depletion on the stability and suppressive ability of eTreg and TFR cells, our findings suggest that targeting Blimp1+ eTreg may generate similar anti-tumor effects while limiting systemic toxicity. Here, PRDM1 is linked to neoplasm.